Temozolomide + IL-2 + IFN + GM-CSF

Indication

Metastatic cancer

• Temozolomide (Temodar) 150-200 mg/m2/d po d1-5
• IL-2 4 MU/m2/d sc d6-17
• IFN- α-2b 5 MU/d sc d6-17
• GM-CSF 125 mcg/m2/d (max 250 mcg/d) sc d6-17
• Q4w

References

Robert WW et al. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon- α-2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol 2005; 23:8992